Henry Schein reported its highest-ever Q3 revenue at $3.22 billion, supported by growth across all major business segments. Non-GAAP EPS rose to $1.38, and the company raised its full-year EPS guidance.

Henry Schein delivered a mixed performance in the second quarter of 2025. While total net sales saw a modest increase of 3.3% to $3.2 billion, driven by growth in Global Medical Distribution, Global Specialty Products, and Global Technology, GAAP and non-GAAP diluted EPS both declined compared to the prior year. The company noted lower margins in the U.S. due to glove pricing and targeted sales initiatives, but expressed satisfaction with these initiatives and a return to normal promotional activity. Henry Schein is maintaining its full-year 2025 guidance, anticipating earnings to be weighted towards the second half of the year.

Henry Schein delivered a solid Q1 2025 performance with $3.17 billion in revenue and a net income of $110 million. Non-GAAP EPS reached $1.15, supported by gains in medical distribution and specialty products, despite restructuring costs and a decline in dental equipment sales.

Henry Schein Inc. delivered a solid fourth quarter, achieving a 5.8% increase in total net sales. GAAP net income surged to $94 million, and non-GAAP net income increased to $149 million. Adjusted EBITDA also rose significantly to $270 million, reflecting strong operational performance. The company’s restructuring efforts contributed to cost efficiencies, supporting future growth.

Henry Schein's third-quarter results for 2024 showed a slight increase in total net sales, driven by acquisitions and the successful implementation of their BOLD+1 Strategic Plan. The company's GAAP diluted EPS was $0.78, and non-GAAP diluted EPS was $1.22. They have increased their full-year non-GAAP EPS guidance to $4.74 to $4.82.

Henry Schein reported a 1.1% increase in total net sales for the quarter, reaching $3.1 billion. GAAP diluted EPS was $0.80, while non-GAAP diluted EPS was $1.23. The company updated its full-year non-GAAP EPS guidance to $4.70 to $4.82 and announced a new restructuring plan targeting $75 million to $100 million in annual run-rate savings.

Henry Schein's first-quarter financial results for 2024 reflect solid earnings driven by gross margin expansion and a strong recovery from last quarter’s cyber incident. The company reported a sales growth of 3.7% compared to the first quarter of 2023.

Henry Schein reported Q4 2023 financial results, with total net sales of $3.0 billion, a decrease of 10.5% compared to Q4 2022. GAAP net income was $18 million, or $0.13 per diluted share, and non-GAAP net income was $86 million, or $0.66 per diluted share. The results were impacted by a cybersecurity incident and acquisition-related expenses.

Henry Schein reported a 3.1% increase in total net sales, reaching $3.2 billion. GAAP diluted EPS was $1.05, and non-GAAP diluted EPS was $1.32. The company is updating its full-year non-GAAP diluted EPS guidance to $4.43 to $4.71, reflecting softening macroeconomic conditions and the impact of a recent cybersecurity incident.

Henry Schein reported a 2.3% increase in total net sales for Q2 2023, reaching $3.1 billion. GAAP diluted EPS was $1.06, while non-GAAP diluted EPS was $1.31. The company affirms its 2023 non-GAAP diluted EPS guidance of $5.18 to $5.35.

Henry Schein reported a decrease of 3.8% in net sales compared to Q1 2022, with sales totaling $3.1 billion. GAAP diluted EPS was $0.91, and non-GAAP diluted EPS was $1.21. Excluding PPE products and COVID-19 test kits, internal sales growth in local currencies was 6.3%. The company is updating its full-year 2023 non-GAAP diluted EPS guidance to $5.18 to $5.35.

Henry Schein reported a slight increase in fourth-quarter net sales, but GAAP diluted EPS decreased significantly. The company introduced 2023 financial guidance, expecting operating income growth when excluding the contribution from PPE products and COVID-19 test kits.

Henry Schein reported a decrease in net sales by 3.5% compared to Q3 2021, but an increase in non-GAAP diluted EPS from $1.10 to $1.15. The company's internal sales increased by 6.8% in local currencies when excluding sales of PPE and COVID-19 test kits. The company narrows its 2022 non-GAAP diluted EPS guidance range, reflecting confidence in the business's strength.

Henry Schein reported a 2.1% increase in net sales, reaching $3.0 billion. GAAP diluted EPS increased to $1.16, compared to $1.10 in the second quarter of 2021. The company reaffirmed its full-year 2022 GAAP diluted EPS guidance range of $4.75 to $4.91.

Henry Schein reported record first-quarter financial results with net sales of $3.2 billion, an increase of 8.7% compared to the first quarter of 2021. GAAP diluted EPS was $1.30, compared to $1.16 in the first quarter of 2021. The company affirmed its full-year 2022 GAAP diluted EPS guidance of $4.75 to $4.91.

Henry Schein reported Q4 2021 total net sales of $3.3 billion, up 5.2% compared with prior-year. Fourth-quarter GAAP diluted EPS from continuing operations of $1.05 compared with prior-year GAAP diluted EPS from continuing operations of $0.99. Fourth-quarter non-GAAP diluted EPS from continuing operations of $1.07 compared with prior-year non-GAAP diluted EPS from continuing operations of $1.00.

Henry Schein reported record third-quarter financial results with net sales of $3.2 billion, up 11.9% year-over-year. GAAP diluted EPS was $1.15, compared to $0.99 in the prior year, and non-GAAP diluted EPS was $1.10, compared to $1.03 in the prior year. The company increased its 2021 non-GAAP diluted EPS guidance to a range of $4.27 to $4.35 and introduced preliminary guidance for 2022.

Henry Schein reported record second-quarter financial results from continuing operations, with total net sales of $3.0 billion, up 76.2% compared to the prior year and up 21.2% versus 2019. GAAP diluted EPS was $1.10, and non-GAAP diluted EPS was $1.11. The company raised its guidance for 2021 non-GAAP diluted EPS to be at or above $3.85.

Henry Schein reported record first-quarter financial results from continuing operations, with total net sales of $2.9 billion, a 20.4% increase compared to the first quarter of 2020. GAAP diluted EPS from continuing operations was $1.16, and non-GAAP diluted EPS from continuing operations was $1.24. The company raised its guidance for 2021 non-GAAP diluted EPS to be at or above $3.70.

Henry Schein reported a strong Q4 2020 with total net sales reaching $3.2 billion, an 18.6% increase year-over-year, driven primarily by PPE and COVID-19 related product sales. GAAP diluted EPS was $0.99, while non-GAAP diluted EPS was $1.00. The company's dental and medical segments showed growth, with medical experiencing a significant surge due to COVID-19 related demand.

Henry Schein reported record third quarter financial results, with net sales reaching $2.8 billion, a 13.2% increase compared to the third quarter of 2019. GAAP diluted EPS from continuing operations was $0.99, and non-GAAP diluted EPS from continuing operations was $1.03. The company's performance was driven by sales of PPE and COVID-19-related products.

Henry Schein reported a decrease in net sales by 31.2% compared to Q2 2019, with a GAAP net loss of $11.4 million, or $0.08 per diluted share. The results reflect the impact of COVID-19, particularly in the Dental business, but sales improved as the quarter progressed due to the resumption of operations for dental and medical customers.

Henry Schein reported a 2.9% increase in net sales to $2.4 billion for Q1 2020. GAAP diluted EPS from continuing operations was $0.91, and non-GAAP diluted EPS was $0.94. The company's results were significantly impacted by the COVID-19 pandemic, particularly in the Dental business.

Henry Schein reported a 7.9% increase in net sales from continuing operations, reaching $2.7 billion. GAAP diluted EPS was $2.25, up 192.2% year-over-year, while non-GAAP diluted EPS was $0.97, a 9.0% increase. The company affirms its 2020 non-GAAP diluted EPS guidance of $3.65 to $3.75.